about
Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatmentsNovel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interactionDifferential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies.Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assayAspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test.Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics.P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activationAntiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.Activation of neuronal transient receptor potential vanilloid 1 channel underlies 20-hydroxyeicosatetraenoic acid-induced vasoactivity: role for protein kinase A.Letter by Wallace and Chan regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin".Platelet responses to pharmacological and physiological interventions in middle-aged men with different habitual physical activity levels.Inhibition of profibrotic microRNA-21 affects platelets and their releasateNot all light transmission aggregation assays are created equal: qualitative differences between light transmission and 96-well plate aggregometry96-well plate-based aggregometry.Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testingStandardised optical multichannel (optimul) platelet aggregometry using high-speed shaking and fixed time point readings
P50
Q26998572-A8F354C3-AAE7-466D-B626-1BB313D7EC42Q36027470-0DBAA360-0F77-4534-9FD4-DDF6C81E3686Q37138984-3E353CF9-C86A-44E5-9B1D-C54A795A633DQ37203951-9C82A12B-28A6-4DD6-9726-6C5F79C5E61EQ37596628-F72A53C5-3CE8-4536-B018-B9E6860B31BBQ37681393-D3EBD5BC-2EAA-4BA0-A498-6FCB28598804Q38196425-5ECA6099-ECBB-47CD-AB33-F11CBB9C7412Q39221284-8860F966-34F7-416D-8AB6-70B5CDC6CBC7Q43226900-E0D371AA-0670-4BBA-BA16-35D0B6A7482DQ44073136-594B90AE-F307-4DCE-B7CA-91BF4848EF97Q44272261-291F737D-074C-4131-801D-51A2FAC3E7CEQ48316936-D627CE86-4351-4D59-A7A7-81A0715D5CE5Q58617301-8B18E5BF-785A-4DF0-8C3E-FA97FB94EE87Q63407963-E2509C0A-E6C1-4FD5-AD7A-3044E0367DFDQ64936727-EBA172EA-98CF-4FE6-8BA4-BF2BF525F051Q84632897-66A3FF1B-6B84-407C-8754-BC48681FCE77Q84632907-BAACA741-733E-47F5-9B0A-2D89101307F7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Melissa V Chan
@ast
Melissa V Chan
@en
Melissa V Chan
@es
Melissa V Chan
@nl
type
label
Melissa V Chan
@ast
Melissa V Chan
@en
Melissa V Chan
@es
Melissa V Chan
@nl
prefLabel
Melissa V Chan
@ast
Melissa V Chan
@en
Melissa V Chan
@es
Melissa V Chan
@nl
P106
P31
P496
0000-0003-2154-1386